JP2013545762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013545762A5 JP2013545762A5 JP2013541248A JP2013541248A JP2013545762A5 JP 2013545762 A5 JP2013545762 A5 JP 2013545762A5 JP 2013541248 A JP2013541248 A JP 2013541248A JP 2013541248 A JP2013541248 A JP 2013541248A JP 2013545762 A5 JP2013545762 A5 JP 2013545762A5
- Authority
- JP
- Japan
- Prior art keywords
- lacosamide
- weight
- formulation
- matrix
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 49
- 229960002623 lacosamide Drugs 0.000 claims 49
- 239000000203 mixture Substances 0.000 claims 35
- 238000009472 formulation Methods 0.000 claims 34
- 239000011159 matrix material Substances 0.000 claims 20
- 238000002360 preparation method Methods 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 238000013270 controlled release Methods 0.000 claims 6
- 238000010828 elution Methods 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 239000000654 additive Substances 0.000 claims 5
- 239000007864 aqueous solution Substances 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- 230000036470 plasma concentration Effects 0.000 claims 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- -1 hydroxypropyl Chemical group 0.000 claims 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 4
- 239000000314 lubricant Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 229920002678 cellulose Polymers 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 229920000609 methyl cellulose Polymers 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical class CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 238000001647 drug administration Methods 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000010981 methylcellulose Nutrition 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 239000004925 Acrylic resin Substances 0.000 claims 1
- 229920000178 Acrylic resin Polymers 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 239000006057 Non-nutritive feed additive Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000001761 ethyl methyl cellulose Substances 0.000 claims 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41915310P | 2010-12-02 | 2010-12-02 | |
| US41915810P | 2010-12-02 | 2010-12-02 | |
| EP10193561.7 | 2010-12-02 | ||
| US61/419,153 | 2010-12-02 | ||
| EP10193559.1 | 2010-12-02 | ||
| EP10193561A EP2468261A1 (en) | 2010-12-02 | 2010-12-02 | Formulation of lacosamide |
| EP10193559 | 2010-12-02 | ||
| US61/419,158 | 2010-12-02 | ||
| US201161444439P | 2011-02-18 | 2011-02-18 | |
| US201161444447P | 2011-02-18 | 2011-02-18 | |
| US61/444,439 | 2011-02-18 | ||
| US61/444,447 | 2011-02-18 | ||
| US201161485354P | 2011-05-12 | 2011-05-12 | |
| US201161485361P | 2011-05-12 | 2011-05-12 | |
| US61/485,361 | 2011-05-12 | ||
| US61/485,354 | 2011-05-12 | ||
| PCT/EP2011/006027 WO2012072256A2 (en) | 2010-12-02 | 2011-12-01 | Once daily formulation of lacosamide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016202383A Division JP6357687B2 (ja) | 2010-12-02 | 2016-10-14 | ラコサミドの１日１回投与用製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013545762A JP2013545762A (ja) | 2013-12-26 |
| JP2013545762A5 true JP2013545762A5 (cg-RX-API-DMAC7.html) | 2015-01-22 |
| JP6027539B2 JP6027539B2 (ja) | 2016-11-16 |
Family
ID=46172318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013541248A Active JP6027539B2 (ja) | 2010-12-02 | 2011-12-01 | ラコサミドの１日１回投与用製剤 |
| JP2016202383A Active JP6357687B2 (ja) | 2010-12-02 | 2016-10-14 | ラコサミドの１日１回投与用製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016202383A Active JP6357687B2 (ja) | 2010-12-02 | 2016-10-14 | ラコサミドの１日１回投与用製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20130251813A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3766485A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6027539B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101980386B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103561727B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011335415B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013013525A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2817654A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA029180B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL226231B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013005974A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ610701A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2012072256A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201303289B (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
| CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| EP1873527A1 (en) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
| TWI397417B (zh) | 2006-06-15 | 2013-06-01 | Ucb Pharma Gmbh | 具有協同抗驚厥功效之醫藥組成物 |
| US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| EP2468261A1 (en) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
| CN102805733B (zh) * | 2011-06-01 | 2016-03-09 | 日东电工株式会社 | 颗粒制剂及其制造方法 |
| US8779355B2 (en) | 2011-12-28 | 2014-07-15 | Quest Diagnostics Investments, Inc. | Methods for detecting lacosamide by mass spectrometry |
| KR101732731B1 (ko) | 2013-04-02 | 2017-05-08 | 주식회사 바이오파마티스 | 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물 |
| WO2014180895A1 (en) * | 2013-05-08 | 2014-11-13 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical formulations of lacosamide |
| EP2878296A1 (en) * | 2013-11-29 | 2015-06-03 | UCB Pharma GmbH | Pharmaceutical composition comprising lacosamide and levetiracetam |
| WO2015079010A2 (en) * | 2013-11-29 | 2015-06-04 | Ucb Pharma Gmbh | Pharmaceutical composition comprising lacosamide and levetiracetam |
| AU2015258900B2 (en) * | 2014-05-16 | 2020-07-09 | Vivus Llc | Orally administrable formulations for the controlled release of a pharmacologically active agent |
| US20180021307A1 (en) * | 2015-02-20 | 2018-01-25 | Ucb Biopharma Sprl | Combination Treatment |
| JO3543B1 (ar) * | 2015-09-28 | 2020-07-05 | Applied Pharma Res | تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم |
| EP3355865B8 (en) | 2015-09-29 | 2025-02-19 | Merz Pharmaceuticals, LLC | Sustained release compositions of 4-aminopyridine |
| JP6902033B2 (ja) * | 2015-12-30 | 2021-07-14 | アダマス ファーマシューティカルズ， インコーポレイテッド | 発作−関連障害の処置のための方法および組成物 |
| KR102544141B1 (ko) * | 2016-09-29 | 2023-06-16 | 에스케이케미칼 주식회사 | 라코사미드 서방성 제제 |
| CN106551900A (zh) * | 2016-12-05 | 2017-04-05 | 北京万全德众医药生物技术有限公司 | 一种拉科酰胺口服溶液及其制备工艺 |
| LT3551189T (lt) | 2016-12-09 | 2024-02-12 | Alexza Pharmaceuticals, Inc. | Alprazolamas, skirtas vartoti gydant epilepsiją |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR102852740B1 (ko) | 2018-02-02 | 2025-08-29 | 알렉스자 파마스티칼즈, 인크. | 전기적 응축 에어로졸 디바이스 |
| KR102083241B1 (ko) | 2018-02-14 | 2020-03-02 | 환인제약 주식회사 | 라코사미드를 함유하는 약제학적 서방성 조성물 |
| CN110833528A (zh) * | 2018-08-17 | 2020-02-25 | 北京万全德众医药生物技术有限公司 | 一种拉科酰胺脂质体冻干粉针剂及其制备方法 |
| CN109010301B (zh) * | 2018-09-05 | 2021-01-26 | 上海上药第一生化药业有限公司 | 一种拉考沙胺晶型ii片剂及其制备方法和应用 |
| US12042474B2 (en) | 2019-06-06 | 2024-07-23 | Shanghai Aucta Pharmaceuticals Co., Ltd. | Lacosamide pharmaceutical composition and dosage form thereof |
| CA3148705A1 (en) * | 2019-06-06 | 2020-12-10 | Shaoqiong LYU | Lacosamide pharmaceutical composition and pharmaceutical preparation thereof |
| CN112022804A (zh) * | 2020-09-28 | 2020-12-04 | 健民药业集团股份有限公司 | 一种拉考沙胺口服溶液及制备方法 |
| EP4309648A4 (en) * | 2021-03-17 | 2025-03-05 | Shanghai Yonsun Biotechnology Co., Ltd. | PHARMACEUTICAL LACOSAMIDE COMPOSITION, MANUFACTURING PROCESS THEREOF AND APPLICATIONS THEREOF |
| WO2024054987A1 (en) * | 2022-09-08 | 2024-03-14 | The Children's Hospital Of Philadlphia | Gpcr latrophilin-3 as biomarker for detecting increased risk for mild brain injury and methods of use thereof for diagnosis and treatment of the same |
| CN115581676A (zh) * | 2022-09-30 | 2023-01-10 | 澳美制药(苏州)有限公司 | 拉考沙胺片剂及其制备工艺 |
| US12478587B1 (en) | 2025-02-06 | 2025-11-25 | Shanghai Aucta Pharmaceuticals Co., Ltd. | Formulation for lacosamide |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT888289E (pt) | 1996-03-15 | 2001-09-28 | Res Corp Technologies Inc | Derivados enantiomericos de aminoacidos anticonvulsivos |
| AU744899B2 (en) | 1997-07-15 | 2002-03-07 | Research Corporation Technologies, Inc. | Amino acid derivatives useful to treat stroke |
| DE60120104T2 (de) | 2001-03-20 | 2006-09-21 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz |
| PT1243263E (pt) | 2001-03-21 | 2003-03-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma |
| ATE428413T1 (de) | 2003-12-02 | 2009-05-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen |
| EP1541138A1 (en) | 2003-12-05 | 2005-06-15 | Schwarz Pharma Ag | Novel use of peptide compounds for treating status epilepticus or related conditions |
| US20060009384A1 (en) | 2003-12-05 | 2006-01-12 | David Rudd | Novel use of peptide compounds for treating status epilepticus or related conditions |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| EP1579858A1 (en) | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
| CA2562937A1 (en) | 2004-04-16 | 2005-10-27 | Schwarz Pharma Ag | Use of peptidic compounds for the prophylaxis and treatment of chronic headache |
| EP1604654A1 (en) | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating dyskinesia |
| EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| US7427601B2 (en) | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| NZ552651A (en) | 2004-08-27 | 2010-07-30 | Sanol Arznei Schwarz Gmbh | Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
| JP2006124385A (ja) * | 2004-09-30 | 2006-05-18 | Takeda Chem Ind Ltd | 放出制御製剤 |
| US20060105663A1 (en) * | 2004-10-04 | 2006-05-18 | Stefan Greulich | Polymer assemblies with decorative surfaces |
| EA014249B1 (ru) * | 2005-01-27 | 2010-10-29 | Алембик Лимитед | Формуляция леветирацетама длительного высвобождения |
| WO2006079547A2 (en) | 2005-01-28 | 2006-08-03 | Schwarz Pharma Ag | Spm 927 for add-on therapy of schizophrenia |
| BRPI0612802A2 (pt) * | 2005-07-07 | 2010-11-30 | Farnam Co Inc | composições farmacêuticas de liberação sustentada para medicamentos extremamente hidrossolúveis |
| EP1754476A1 (en) | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| WO2007120485A2 (en) * | 2006-03-30 | 2007-10-25 | Cinergen, Llc | Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor |
| EP1920780A1 (en) | 2006-10-12 | 2008-05-14 | Schwarz Pharma Ag | Peptide compounds for the treatment of hyperexcitability disorders |
| TWI397417B (zh) | 2006-06-15 | 2013-06-01 | Ucb Pharma Gmbh | 具有協同抗驚厥功效之醫藥組成物 |
| EP1925314A1 (en) | 2006-11-22 | 2008-05-28 | Schwarz Pharma Ag | Pharmaceutical composition with synergistic anticonvulsant effect |
| CN101466390B (zh) | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| EP1873527A1 (en) | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
| US20080014271A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
| ES2365574T3 (es) * | 2007-01-11 | 2011-10-07 | Xenoport, Inc. | Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento. |
| US20120003307A1 (en) | 2007-11-29 | 2012-01-05 | Ranbaxy Laboratories Limited | Levetiracetam controlled release composition |
| US20090143362A1 (en) | 2007-12-04 | 2009-06-04 | Barabde Umesh Vinayakrao | Carbamazepine formulations |
| DE102008059155A1 (de) * | 2008-11-27 | 2010-06-02 | Ratiopharm Gmbh | Trockenverarbeitung und neue Formen von Lacosamid |
| KR100980999B1 (ko) * | 2008-11-28 | 2010-09-07 | 기아자동차주식회사 | 차량용 시거라이터조립체 |
| WO2010148300A1 (en) | 2009-06-19 | 2010-12-23 | The University Of North Carolina At Chapel Hill | Methods of treatment of neurological disorders |
| WO2011037833A2 (en) | 2009-09-23 | 2011-03-31 | The University Of North Carolina At Chapel Hill | Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| US10786464B2 (en) * | 2009-11-03 | 2020-09-29 | Lupin Limited | Modified release formulation of lacosamide |
| WO2011101863A2 (en) * | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of lacosamide |
-
2011
- 2011-12-01 JP JP2013541248A patent/JP6027539B2/ja active Active
- 2011-12-01 WO PCT/EP2011/006027 patent/WO2012072256A2/en not_active Ceased
- 2011-12-01 EP EP20188230.5A patent/EP3766485A1/en not_active Withdrawn
- 2011-12-01 CN CN201180057820.9A patent/CN103561727B/zh not_active Expired - Fee Related
- 2011-12-01 EP EP11817472.1A patent/EP2646001A2/en not_active Withdrawn
- 2011-12-01 US US13/990,863 patent/US20130251813A1/en not_active Abandoned
- 2011-12-01 BR BR112013013525A patent/BR112013013525A2/pt not_active Application Discontinuation
- 2011-12-01 EA EA201390804A patent/EA029180B1/ru not_active IP Right Cessation
- 2011-12-01 EP EP11791442.4A patent/EP2645997B1/en not_active Revoked
- 2011-12-01 MX MX2013005974A patent/MX2013005974A/es not_active Application Discontinuation
- 2011-12-01 CA CA 2817654 patent/CA2817654A1/en not_active Abandoned
- 2011-12-01 NZ NZ610701A patent/NZ610701A/en not_active IP Right Cessation
- 2011-12-01 AU AU2011335415A patent/AU2011335415B2/en not_active Ceased
- 2011-12-01 WO PCT/EP2011/006026 patent/WO2012084126A2/en not_active Ceased
-
2012
- 2012-02-01 KR KR1020137017171A patent/KR101980386B1/ko not_active Expired - Fee Related
-
2013
- 2013-05-07 ZA ZA2013/03289A patent/ZA201303289B/en unknown
- 2013-05-08 IL IL226231A patent/IL226231B/en active IP Right Grant
-
2014
- 2014-10-21 US US14/519,338 patent/US20150104507A1/en not_active Abandoned
-
2016
- 2016-10-14 JP JP2016202383A patent/JP6357687B2/ja active Active
-
2018
- 2018-07-05 US US16/027,963 patent/US20190008758A1/en not_active Abandoned
- 2018-08-21 US US16/106,655 patent/US20190054009A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013545762A5 (cg-RX-API-DMAC7.html) | ||
| US8563036B2 (en) | Pharmaceutical compositions comprising Brivaracetam | |
| JP2011504491A (ja) | プレガバリンの制御放出医薬組成物 | |
| RU2012131158A (ru) | Фармацевтическая композиция с контролируемым высвобождением лекарственного средства | |
| JP2008520736A5 (cg-RX-API-DMAC7.html) | ||
| WO2010103544A2 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| JP2011500552A (ja) | 胃腸障害を処置するための医薬用組み合わせおよび組成物 | |
| JP2011503017A (ja) | ヒドロモルホン含有徐放性錠剤 | |
| JP5881700B2 (ja) | ブロナンセリン経口放出制御型医薬組成物 | |
| CN1988889A (zh) | 含托吡酯的缓释制剂及其制备方法 | |
| WO2011101863A2 (en) | Extended release pharmaceutical compositions of lacosamide | |
| JP2013531041A5 (cg-RX-API-DMAC7.html) | ||
| CN103717223A (zh) | 含甘磷酸胆碱或者其药学上可接受的盐的缓释药物组合物及其制造方法 | |
| JP2017532363A5 (cg-RX-API-DMAC7.html) | ||
| CA2642851A1 (en) | Low flush niacin formulation | |
| AU2017252410A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| CN107205950A (zh) | 金刚烷胺组合物的施用方法 | |
| KR101923403B1 (ko) | 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물 | |
| WO2007112574A1 (en) | Extended release composition of venlafaxine | |
| HK1198288A1 (en) | Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate | |
| JP2012515757A (ja) | トリメタジジンの放出調節固形薬剤組成物及びその製造方法 | |
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| CA2777856A1 (en) | Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof | |
| JP2007529564A5 (cg-RX-API-DMAC7.html) | ||
| EP2994112A1 (en) | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof |